메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

퓨처슈티컬스, 뉴로러쉬 소유주 상대 특허 침해 소송 제기…모방 성분 사용 주장

모멘스, 일리노이주, 2025년 9월 15일 -- VDF 퓨처슈티컬스(VDF FutureCeuticals, Inc.)가 아우라 사이언티픽(Aura Scientific)을 상대로 소송을 제기했다. 아우라 사이언티픽의 뇌 기능 개선 성분인 뉴로러쉬(NeuroRush), 즉 전체 커피 열매 추출물이 퓨처슈티컬스가 보유한 커피 열매 관련 기술 특허를 다수 침해했다는 이유다. 문제가 된 특허에는 커피 열매 조성물을 활용해 인지 기능 측정 수치를 개선하는 기술 관련 특허도 포함된다. 퓨처슈티컬스는 이번 소송에서 금전적 손해배상, 고의적 침해 판결, 그리고 침해 성분의 판매 전면 중단을 요구하고 있다. 퓨처슈티컬스는 커피 열매 시장 전체를 개척했으며, 수년간 커피 열매 전체 추출물을 포괄하는 특허를 보유해 왔다. 보유 커피 열매 기술 중에는 퓨처슈티컬스 의뢰로 수행한 다수의 사람 대상 임상 시험을 통해 발견해 공개한, 뇌 기능 개선을 위한 커피 열매 조성물 관련 특허가 포함된다. J. 랜달 웩슬러(J. Randal Wexler) 퓨처슈티컬스 부사장 겸 총괄 법률고문은 이렇게 말했다. "아우라 사이언티픽의 성분 뉴로러쉬는
- 김갑성 기자
- 2025-09-15 20:00
Medit Link Express for iPad Debuts as Medit i900 Mobility Goes into Shipping

SEOUL, South Korea, Sept. 15, 2025 -- Medit (www.medit.com), a global leader in digital dentistry, today announced two milestone moments for the industry. The company has officially launched Medit Link Express, its first iPad-native app for intraoral scanning, now available on the Apple App Store, and at the same time begun shipping the Medit i900 Mobility, previously available for pre-order since August 1. With the Medit i900 Mobility now shipping in select regions, dental professionals can experience a new level of mobility in scanning. Designed for today's clinical e
- 김갑성 기자
- 2025-09-15 19:00
Sunsred Launches FDA-cleared Red Light Therapy Devices for Wellness Brands Worldwide

SHENZHEN, China, Sept. 15, 2025 -- Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices. As a go-to OEM/ODM red light therapy manufacturer in this space, Sunsred is meeting the huge global demand for safe, effective, and certified light therapy solutions. The new range includes everything from LED face masks and flexible therapy belts to versatile light panels, all built for easy customization. This gives health, beauty, and wellness brands a strong advantage in a crowded market. Red Light Ther
- 김갑성 기자
- 2025-09-15 19:00
Clinically Proven Human Milk Probiotic LC40® supports Infant Health and Breastfeeding Mothers

SINGAPORE, Sept. 15, 2025 -- Supported by six clinical studies and two safety trials, Kerry's LC40® is the first probiotic strain of its kind validated for both infant and maternal applications, offering a natural, science-backed approach to early life and maternal health. Human Milk Probiotics are strains of beneficial bacteria, specifically including Lactobacillus and Bifidobacterium, naturally found in breast milk. Kerry, in collaboration with the Complutense University of Madrid, is the first to isolate these strains, including LC40® and BfM26®, using an
- 김갑성 기자
- 2025-09-15 18:20
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

HONG KONG, Sept. 15, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab. COMPASSION-36 is the first global registrational Phase
- 김갑성 기자
- 2025-09-15 12:11
Jointly discovered KAT6i molecule originating from Australian research has initiated Phase 3 in HR+ HER2- Breast Cancer with Pfizer Inc

[ 메디채널 김갑성 기자 ] Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical tr
- 김갑성 기자
- 2025-09-15 12:06
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma

Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients. >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations. Sustained engagement of 12+ months with 54% persistence even in high-risk, elderly patients, far above typical digital health benchmarks (30–45%). Clinically meaningful reductions in admissions,
- 김갑성 기자
- 2025-09-15 12:05
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation 'Data Mining Machine' for Genomics

SHENZHEN, China, Sept. 15, 2025 -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a "data mining machine," the T7+ redefines high-throughput sequencing by combining daily output wit
- 김갑성 기자
- 2025-09-15 11:53
EverBridge Group and Cosmotec Forge Landmark Partnership

SHANGHAI, Sept. 15, 2025 -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence. Simultaneously, the partnership underscores Cosmotec's best-in-class digital commercialization platf
- 김갑성 기자
- 2025-09-15 08:00
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations

SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory milestone for the same product candidate, which previously received both Fast Track and Orphan Drug Designations for the treatme
- 김갑성 기자
- 2025-09-15 08:00

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 07시 20분